1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Shandong Weigao Group Medical Polymer Company Limited

Shandong Weigao Group Medical Polymer Company Limited

SHWGF
Shandong Weigao Group Medical Polymer Company LimitedUS flagOther OTC
0.43
USD
- -
- -
1.91BMarket Cap
Shandong Weigao Group Medical Polymer Company Limited
SHWGF
(Other OTC)

Recent

price

0.43

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.57
0.72
0.82
1.03
1.18
1.32
1.26
1.41
1.97
2.32
2.59
2.93
3.05
2.93
2.88
2.95
Revenue per Share
0.19
0.78
0.22
0.09
0.24
0.25
0.25
0.39
0.33
0.41
0.46
0.51
0.61
0.44
0.46
0.36
Basic EPS, GAAP
0.04
-0.16
-0.05
-0.07
-0.01
-0.02
0.09
-0.06
0.32
0.3
0.4
0.43
0.26
0.47
0.47
0.38
Free Cash Flow per Basic Share
0.03
0.07
0.06
0.06
0.06
0.07
0.06
0.11
0.05
0.16
0.16
0.15
0.16
0.16
0.19
0.23
Dividend per Share
0.05
0.1
1.38
1.41
1.59
1.76
1.93
0.1
0.1
0.1
0.1
0.1
3.94
4.23
4.47
4.62
Book Value per Share
0.79
1.72
1.84
1.86
2.05
2.26
2.57
2.9
2.02
2.53
2.99
3.53
4.04
4.16
4.45
4.65
Tangible Book Value per Share
4,305
4,418
4,476
4,476
4,476
4,476
4,476
4,476
4,476
4,476
4,489
4,501
4,506
4,508
4,539
4,535
Basic Weighted Avg Shares
2,463
3,181
3,689
4,613
5,278
5,919
5,620
6,293
8,809
10,384
11,622
13,209
13,747
13,229
13,087
13,389
Sales/Revenue/Turnover
28.44
26.83
23.49
22.77
21.04
21.46
19.01
21.56
19.55
22.65
21.31
23.27
22.79
17.36
18.23
14.45
Operating Margin (%)
94
98
128
188
244
316
349
365
563
615
709
737
803
912
972
987
Depreciation Expense
799
3,462
996
388
1,085
1,113
1,106
1,729
1,473
1,850
2,087
2,276
2,764
2,002
2,067
1,612
Net Income, GAAP
9.63
3.46
11.53
28.76
14.18
13.98
12.96
14.71
14.56
14.52
13.97
14.6
12.87
12.98
15.31
15.79
Effective Tax Rate (%)
32.45
108.85
27.01
8.41
20.56
18.8
19.68
27.47
16.72
17.82
17.95
17.23
20.11
15.13
15.79
12.04
Profit Margin (%)
1,291
2,789
2,341
4,171
4,796
5,525
5,998
6,751
7,391
8,032
9,768
11,082
12,282
11,052
13,362
15,190
Working Capital
88
63
- -
100
149
649
792
804
5,093
4,454
4,015
3,513
3,501
1,596
2,951
4,605
LT Debt
3,634
8,212
8,920
9,063
9,880
10,787
12,205
13,638
15,191
16,992
18,879
21,047
23,582
23,993
25,342
25,820
Total Equity
18.24
13.67
8.91
8.13
9.65
9.9
7.38
8.25
8.36
9.33
9.32
10.84
10.17
7.06
7.02
5.38
Return on Invested Capital (%)
270.6
787
29.66
6.1
15.31
13.43
11.4
27.65
40.64
31.92
34.2
37.36
18.11
8.92
8.58
6.42
Return on Capital (%)
494.96
1,044.56
30
6.21
16.17
14.83
13.36
37.94
325.7
409.07
461.44
500.59
30.33
10.86
10.49
7.82
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.2%
6.56%
1.89%
Free Cash Flow
-141.09%
6.02%
-19.82%
Net Income, GAAP
6.35%
-3.16%
-21.99%
Sales/Revenue/Turnover
9.19%
3.04%
2.31%
Total Cash Common Dividend
28.28%
8.57%
18.57%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
13,229
2024
- -
- -
- -
- -
13,087
2025
- -
- -
- -
- -
13,389

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.44
2024
- -
- -
- -
- -
0.46
2025
- -
- -
- -
- -
0.36

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.16
2024
- -
- -
- -
- -
0.19
2025
- -
- -
- -
- -
0.23
Similar Companies
Nissan Medical Industries Ltd (NISA.TA)
Kossan Rubber Industries Bhd (KSRBF)
Biotage AB (publ) (BIOT.ST)
OJsys, Inc. (OJSY)
Opsens Inc. (OPS.TO)
Straumann Holding AG (STMN.SW)
Business
Shandong Weigao Group Medical Polymer Company Limited engages in the research, development, production and sale of medical devices primarily in China and internationally. The company operates through segments including medical device products offering safe infusion sets, clinical nursing consumables, perioperative solutions, endocrine devices, urinary catheters, rehabilitation systems and extracorporeal circulation equipment; orthopedic products comprising spine implants, joint replacements, trauma fixation devices, sports medicine tools, bone repair materials and spinal endoscopes; pharmaceutical packaging products such as prefilled syringes, drug delivery systems, automatic drug delivery devices and pharmaceutical consumables; interventional products for tumor, vascular and nursing interventions; blood management products including whole blood collection consumables, blood transfusion equipment and irradiation systems; and others encompassing finance leasing, medical PVC granules and irradiation machines. Founded in 1988 and headquartered in Weihai, Shandong Province, China, the company exports to over 100 countries and serves more than 10,000 global medical units across clinical care, orthopedics, blood purification, intervention and pharmaceutical sectors. Recent developments include the renewal of continuing connected transactions with Weigao Holding extending to 2027, the launch of non-phthalic light-avoiding automatic stop infusion devices and sterile needles obtaining registration certificates in 2024, and a breakthrough in ultra-thin wall high-throughput medical beauty needle technology.

Company News

APIChatGPT

  • defenseworld.net

    Shandong Weigao Medical Polymer Co. (OTCMKTS:SHWGF) Short Interest Up 97.6% in March

  • defenseworld.net

    Shandong Weigao Medical Polymer (SHWGF) to Release Earnings on Friday

  • defenseworld.net

    Shandong Weigao Medical Polymer (OTCMKTS:SHWGF) & AdaptHealth (NASDAQ:AHCO) Financial Analysis